N4 Pharma is a pre-clinical stage specialist pharmaceutical company developing Nuvec®, a unique novel silica nanoparticle technology with patented spiky structure designed to load, protect and deliver nucleic acids (siRNA/DNA/mRNA) intracellularly for use in as gene therapy, cancer therapeutics and vaccines. Established in 2014 and floated on the AIM stock market in May 2017.

Nuvec® is currently in the pre-clinical phase, available for licensing to pharmaceutical and biotech partners for nucleic acid product development and is designed to overcome some of the drawbacks of existing delivery systems.

Learn more

Information for investors

For the latest regulatory news updates, information on the AIM rule 26, company presentations and reports

View investor information here

Latest news and updates

The data – evidence based results

January 4th, 2023|

As a result of recently completed initial testing in vitro on loaded Nuvec®  with two generic siRNA probes, N4 Pharma has created an infographic outlining the key results and detailing how Nuvec®  works to deliver [...]